Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Saved in:
Bibliographic Details
Title: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.
Authors: Sprague SM; NorthShore University Health System, Evanston, Illinois.; University of Chicago Pritzker School of Medicine, Chicago, Illinois., Weiner DE; Tufts Medical Center, Boston, Massachusetts., Tietjen DP; Nephrology Consultants LLC, Huntsville, Alabama., Pergola PE; Renal Associates PA, San Antonio, Texas., Fishbane S; Zucker School of Medicine at Hofstra & Northwell Health, Great Neck, New York., Block GA; US Renal Care, Denver, Colorado., Silva AL; Boise Kidney and Hypertension Institute, Meridian, Idaho., Fadem SZ; Kidney Associates, PLLC and Baylor College of Medicine, Houston, Texas., Lynn RI; Kidney Medical Associates, Bronx, New York., Fadda G; Balboa Nephrology Medical Group, La Mesa, California., Pagliaro L; Ardelyx, Inc., Waltham, Massachusetts., Zhao S; Ardelyx, Inc., Waltham, Massachusetts., Edelstein S; Ardelyx, Inc., Waltham, Massachusetts., Spiegel DM; Ardelyx, Inc., Waltham, Massachusetts., Rosenbaum DP; Ardelyx, Inc., Waltham, Massachusetts.
Source: Kidney360 [Kidney360] 2024 May 01; Vol. 5 (5), pp. 732-742. Date of Electronic Publication: 2024 Feb 07.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology Country of Publication: United States NLM ID: 101766381 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2641-7650 (Electronic) Linking ISSN: 26417650 NLM ISO Abbreviation: Kidney360 Subsets: MEDLINE
Database: MEDLINE Ultimate
Be the first to leave a comment!
You must be logged in first